Northwest Biotherapeutics Overview
- Founded
-
1996
- Status
-
Public
- Employees
-
20
- Stock Symbol
-
NWBO
- Investments
-
2
- Share Price
-
$0.73
- (As of Tuesday Closing)
Northwest Biotherapeutics General Information
Description
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Primary Office
- 4800 Montgomery Lane
- Suite 800
- Bethesda, MD 20814
- United States
+1 (240) 000-0000
Northwest Biotherapeutics Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.73 | $0.74 | $0.39 - $2.05 | $779M | 1.05B | 3.04M | $0.08 |
Northwest Biotherapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 767,103 | 671,624 | 1,130,425 | 144,890 |
| Revenue | 1,086 | 1,005 | 1,291 | 2,410 |
| EBITDA | 63,844 | 184,723 | (520,852) | (17,837) |
| Net Income | 56,586 | 179,126 | (529,821) | (20,812) |
| Total Assets | 31,098 | 40,160 | 32,899 | 10,643 |
| Total Debt | 30,575 | 37,938 | 19,857 | 18,032 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Northwest Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Northwest Biotherapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a
Drug Discovery
Bethesda, MD
20
As of 2021
00000
000000000 -
00000
000000
aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
0000000000000
San Diego, CA
000
As of 0000
00000
000000000 -
00000
000 00
aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volu
0000 000000000
Epalinges, Switzerland
000
As of 0000
00.000
0.000
0000-00-00
00000000
00.000
Add Comparison
Northwest Biotherapeutics Competitors (52)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 - | 00000 |
| 000 000000000000 | Formerly VC-backed | Epalinges, Switzerland | 000 | 00.000 | 00000000 | 00.000 |
| 00000000 00000000 | Corporation | Boston, MA | 0 | 000 | 000000000 | 000 |
| 0000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 000000 | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000&0 |
Northwest Biotherapeutics Executive Team (8)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Marnix Bosch Ph.D | Chief Technology Officer | ||
| Alton Boynton Ph.D | Chief Scientific Officer & Founder | ||
| Les Goldman | Senior Vice President, Business Development | ||
| Linda Powers JD | Chief Executive Officer & Chief Financial Officer, Finance |
Northwest Biotherapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Northwest Biotherapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Northwest Biotherapeutics Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 | 28-Aug-2020 | 0000000000 | 00.00 | Other Devices and Supplies | 00000 000 |
| MithraGen | 01-Jan-2008 | Merger/Acquisition | Biotechnology |
Northwest Biotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
